$60.11 Million in Sales Expected for Amphastar Pharmaceuticals Inc (AMPH) This Quarter

Brokerages forecast that Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) will post sales of $60.11 million for the current quarter, Zacks reports. Three analysts have provided estimates for Amphastar Pharmaceuticals’ earnings. The highest sales estimate is $67.73 million and the lowest is $55.90 million. Amphastar Pharmaceuticals posted sales of $63.54 million in the same quarter last year, which suggests a negative year-over-year growth rate of 5.4%. The firm is scheduled to issue its next earnings report on Monday, March 12th.

On average, analysts expect that Amphastar Pharmaceuticals will report full-year sales of $60.11 million for the current financial year, with estimates ranging from $234.00 million to $247.51 million. For the next fiscal year, analysts anticipate that the company will post sales of $310.99 million per share, with estimates ranging from $300.60 million to $325.30 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that cover Amphastar Pharmaceuticals.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings results on Wednesday, November 8th. The company reported $0.07 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.02 by $0.05. The business had revenue of $57.90 million during the quarter, compared to analyst estimates of $57.23 million. Amphastar Pharmaceuticals had a net margin of 0.12% and a return on equity of 2.30%. The business’s revenue was down 9.8% on a year-over-year basis. During the same period last year, the business earned $0.14 EPS.

A number of equities research analysts recently weighed in on AMPH shares. BMO Capital Markets raised their price target on shares of Amphastar Pharmaceuticals from $16.00 to $17.00 and gave the company a “market perform” rating in a report on Friday, November 10th. BidaskClub raised shares of Amphastar Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, January 19th. Raymond James Financial lowered shares of Amphastar Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $18.00 price target for the company. in a report on Thursday, November 9th. Zacks Investment Research upgraded shares of Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 2nd. Finally, Needham & Company LLC increased their price objective on shares of Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the company a “buy” rating in a research note on Friday, December 1st. Two analysts have rated the stock with a sell rating, two have given a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $20.83.

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 6,226 shares of the stock in a transaction on Friday, December 1st. The shares were sold at an average price of $19.67, for a total transaction of $122,465.42. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Jason B. Shandell sold 18,627 shares of the stock in a transaction on Friday, January 26th. The shares were sold at an average price of $19.42, for a total transaction of $361,736.34. The disclosure for this sale can be found here. Insiders have sold a total of 75,443 shares of company stock worth $1,434,441 over the last quarter. 11.10% of the stock is currently owned by insiders.

Institutional investors have recently bought and sold shares of the company. Nationwide Fund Advisors lifted its position in shares of Amphastar Pharmaceuticals by 11.9% in the 2nd quarter. Nationwide Fund Advisors now owns 49,266 shares of the company’s stock worth $880,000 after buying an additional 5,233 shares during the last quarter. Northern Trust Corp lifted its position in shares of Amphastar Pharmaceuticals by 2.0% in the 2nd quarter. Northern Trust Corp now owns 485,706 shares of the company’s stock worth $8,675,000 after buying an additional 9,672 shares during the last quarter. GSA Capital Partners LLP bought a new position in shares of Amphastar Pharmaceuticals in the 3rd quarter worth about $400,000. BNP Paribas Arbitrage SA lifted its position in shares of Amphastar Pharmaceuticals by 70.2% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 17,946 shares of the company’s stock worth $321,000 after buying an additional 7,401 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its position in shares of Amphastar Pharmaceuticals by 7.2% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 218,080 shares of the company’s stock worth $3,895,000 after buying an additional 14,646 shares during the last quarter. Institutional investors own 43.94% of the company’s stock.

Shares of Amphastar Pharmaceuticals (NASDAQ AMPH) opened at $17.94 on Thursday. The firm has a market cap of $824.80, a price-to-earnings ratio of 116.93, a P/E/G ratio of 1.23 and a beta of 1.51. Amphastar Pharmaceuticals has a fifty-two week low of $12.05 and a fifty-two week high of $19.95. The company has a current ratio of 3.08, a quick ratio of 1.86 and a debt-to-equity ratio of 0.13.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another domain, it was stolen and republished in violation of United States and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/08/60-11-million-in-sales-expected-for-amphastar-pharmaceuticals-inc-amph-this-quarter.html.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Get a free copy of the Zacks research report on Amphastar Pharmaceuticals (AMPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply